Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESN364 in women with polycystic ovary syndrome
NL-OMON43634Phase 2Active, not recruiting
- Sponsor
- Ogeda
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fezolinetant in polycystic ovary syndrome (PCOS) (3 arms), sponsored by Ogeda. Primary endpoint: Change in total testosterone from baseline to Week 12. Started Nov 2015; status: active, not recruiting.
02
Drugs
fezolinetant
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NL-OMON43634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43634.